Providence Health & Services

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Established: 1859-01-01

Employees: 10K

Market Cap: -

Website: http://www.providence.org

Clinical Trials

A Systems Approach to Understanding Disease Processes in Multiple Sclerosis

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: All patients in the study will be treated with ocrelizumab

First Posted Date: 2021-10-18

Last Posted Date: 2024-10-02

Lead Sponsor: Providence Health & Services

Target Recruit Count: 14

Registration Number: NCT05081700

Locations: 🇺🇸
Providence Neurological Specialties West, Portland, Oregon, United States
🇺🇸
Swedish Medical Center Multiple Sclerosis Center, Seattle, Washington, United States

Sema 4A as a Marker for Inflammatory Disease in Multiple Sclerosis

Withdrawn

Conditions: Relapsing Multiple Sclerosis
Multiple Sclerosis

Interventions: Diagnostic Test: Cerebrospinal and Blood Serum Semaphorin 4A Levels

First Posted Date: 2021-10-14

Last Posted Date: 2023-08-07

Lead Sponsor: Providence Health & Services

Registration Number: NCT05077956

Locations: 🇺🇸
Providence St. Vincent Medical Center, Portland, Oregon, United States

GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients

Phase 2

Withdrawn

Conditions: Metastatic Melanoma
Head and Neck Squamous Cell Carcinoma

Interventions: Drug: GR-MD-02
Drug: Placebo
Drug: Pembrolizumab

First Posted Date: 2021-08-03

Last Posted Date: 2023-06-06

Lead Sponsor: Providence Health & Services

Registration Number: NCT04987996

Locations: 🇺🇸
Portland Providence Medical Center, Portland, Oregon, United States

Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC)

Phase 2

Recruiting

Conditions: Head and Neck Cancer
Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Pembrolizumab
Radiation: Stereotactic Body Radiation Therapy (5 days)
Procedure: Surgical Resection

First Posted Date: 2021-06-24

Last Posted Date: 2024-01-25

Lead Sponsor: Providence Health & Services

Target Recruit Count: 28

Registration Number: NCT04938609

Locations: 🇺🇸
University of San Diego, San Diego, California, United States
🇺🇸
Portland Providence Medical Center, Portland, Oregon, United States
🇺🇸
Providence St. Vincent Medical Center, Portland, Oregon, United States

Tucatinib With Chemotherapy and Trastuzumab in Advanced Her-2-neu Overexpressing, Previously Treated Breast Cancer.

Phase 1

Withdrawn

Conditions: Breast Cancer Stage IV

Interventions: Drug: Tucatinib

First Posted Date: 2021-05-21

Last Posted Date: 2023-06-22

Lead Sponsor: Providence Health & Services

Registration Number: NCT04896320

Locations: 🇺🇸
Providence Newberg Medical Center, Newberg, Oregon, United States
🇺🇸
Portland Providence Medical Center, Portland, Oregon, United States
🇺🇸
Providence Cancer Institute - Clackamas Clinic, Clackamas, Oregon, United States

and more 1 locations

Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer

Phase 1

Active, not recruiting

Conditions: Breast Cancer

Interventions: Biological: DPX-Survivac
Drug: Letrozole 2.5mg
Radiation: XRT 10Gy x2
Drug: Cyclophosphamide 50mg

First Posted Date: 2021-05-20

Last Posted Date: 2024-01-25

Lead Sponsor: Providence Health & Services

Target Recruit Count: 6

Registration Number: NCT04895761

Locations: 🇺🇸
Providence Portland Medical Center, Portland, Oregon, United States

Efficacy of COVID-19 Vaccination in Patients With Multiple Sclerosis Treated With Immune Modulating Medication

Terminated

Conditions: Multiple Sclerosis

Interventions: Other: Analysis of cell-mediated and antibody-mediated immunity to SARS-CoV-2 virus

First Posted Date: 2021-03-15

Last Posted Date: 2023-04-03

Lead Sponsor: Providence Health & Services

Target Recruit Count: 20

Registration Number: NCT04796584

Locations: 🇺🇸
Providence Neurological Specialties West, Portland, Oregon, United States

CORVax12: SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine Trial for COVID-19 (SARS-CoV-2)

Phase 1

Terminated

Conditions: SARS-CoV-2

Interventions: Drug: CORVax
Drug: IL-12 plasmid
Device: Cliniporator

First Posted Date: 2020-11-13

Last Posted Date: 2024-10-26

Lead Sponsor: Providence Health & Services

Target Recruit Count: 16

Registration Number: NCT04627675

Locations: 🇺🇸
Providence Portland Medical Center, Portland, Oregon, United States

Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)

Phase 1

Active, not recruiting

Conditions: Malignant Epithelial Neoplasms

Interventions: Biological: TCR-transduced T cells
Drug: CDX-1140
Drug: Pembrolizumab

First Posted Date: 2020-08-20

Last Posted Date: 2024-08-23

Lead Sponsor: Providence Health & Services

Target Recruit Count: 24

Registration Number: NCT04520711

Locations: 🇺🇸
Providence Portland Medical Center, Portland, Oregon, United States

Phase Ib Trial of Multivalent Autophagosome Vaccine With or Without GITR Agonist, With Anti-PD-1 Immunotherapy in HNSCC

Phase 1

Recruiting

Conditions: Cancer of the Head and Neck

Interventions: Drug: INCMGA00012
Drug: INCAGN01876
Biological: DPV-001

First Posted Date: 2020-07-14

Last Posted Date: 2024-06-21

Lead Sponsor: Providence Health & Services

Target Recruit Count: 56

Registration Number: NCT04470024

Locations: 🇺🇸
Portland Providence Medical Center, Portland, Oregon, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy